Wesolowski R*, Stover DG*, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. “Phase I study of veliparib on an intermittent and continuous schedule in combination with carboplatin in metastatic breast cancer: A safety and [18F]-fluorothymidine PET biomarker study.” Oncologist. 2020. May 26. [Epub ahead of print]. PMID: 32452601
*Authors contributed equally
Adams EJ, Asad S, Reinbolt R, Collier KA, Abdel-Rasoul M, Gillespie S, Chen JL, Cherian MA, Noonan AM, Sardesai, VanDeusen J, Wesolowski R, Williams N, Shapiro CL, Macrae ER, Pilarski R, Toland AE, Senter L, Ramaswamy R, Lee CN, Lustberg MB, Stover DG. “Metastatic breast cancer patient perceptions of somatic tumor genomic testing.” BMC Cancer. 2020. 20:389. PMID: 32375690
Stover DG*, Reinbolt RE*, Adams EJ, Asad S, Tolliver K, Abdel-Rasoul M, Timmers CD, Gillespie S, Chen JL, Ali SM, Webster J, Collier KA, Cherian MA, Noonan AM, Sardesai S, Vandeusen J, Wesolowski R, Williams N, Lee CN, Shapiro CL, Macrae ER, Ramaswamy B, Lustberg MB. “Prospective Decision-Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.” JCO Precision Oncology (2019). In Press
*Indicates authors contributed equally
Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. “Aggressive Subsets of Metastatic Triple-Negative Breast Cancer.” Clinical Breast Cancer (2019). 19: 30160. PMID: 31631016
Waks AG*, Stover DG*, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock JA, Wesolowski R, Li Z, Damicis A, Danaher P, Brauer HA, Hoadley KA, Rodig S, Goldberg M, Perou CM, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. “The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy.” Clinical Cancer Research (2019). 25: 4644-4655. PMID: 31061067
*Indicates authors contributed equally
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zhang J, Li B, Li X, Zheng Y, Ren L, Hou W, Zhao S, Gong Y, Ren YX, Zhang C, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, BaiF, Li DQ, Wang P, Shi L, Huang W, Shao ZM. “Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.” Cancer Cell (2019). 35: 428-440.e5. PMID: 30853353
Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, Hutchinson JN, Freedman RA, Mittendorf EA, McAllister SS. “Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.” Cancer Discovery (2019). 9:1208-1227. PMID: 31217296
Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman S, Rhoades J, Reed S, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O’Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA. “Tumor fraction in cfDNA as a biomarker in prostate cancer.” JCI Insight (2018). 3(21). Pii:122109. PMID: 30385733
Mathe E, Hays JL, Stover DG, Chen JL. “The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources.” Yearbook of Medical Informatics (2018). 27:211-222. PMID: 30157526
Takahashi N, Chen HY, Harris IS, Stover DG, Yeung T, Bronson RT, Takemura K, Kitao A, Deraedt T, Cichowski K, Mori Y, Mills GB, Brugge, JS. “Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative Stress Tolerance.” Cancer Cell (2018). 33:985-1003. PMID: 29805077
Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K & Lin NU. “Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.” npj Breast Cancer. 2018. 4:10. Open Access
Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP. “Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.” Breast Cancer Research and Treatment. 2018. May 7 [Epub before print]. PMID: 29736741
Leon-Ferre RA, Stover DG. “Supporting the Future of the Oncology Workforce: ASCO Medical Student and Trainee Initiatives.” Journal of Oncology Practice. 2018. 14:277-280. PMID: 29676949
Lustberg MB, Stover DG, Chalmers JJ. “Implementing liquid biopsies in clinical trials: State of affairs, opportunities and challenges.” The Cancer Journal: The Journal of Principles & Practice of Oncology. 2018. [Epub before print]. PMID: 29601331
Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwartz LJ, Giltnane JM, Estrada ME, Servetto A, Gavila J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, Andre F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. “ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.” Clinical Cancer Research (2018). [Epub before print] PMID: 29581135
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. “Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.” Journal of Clinical Oncology. 2018. 36:543-553 PMID: 29298117
Selfors LM, Stover DG, Harris IS, Brugge JS, Coloff JL. “Identification of cancer genes that are independent of dominant proliferation and lineage programs.” Proceedings of the National Academy of Sciences U.S.A. 2017. 114:E11276-E11284 [Epub before print] PMID: 29229826
Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis J, Zhang CZ, Cohen O, Oh C, Ding H, Lloyd MR, Mahmud S, Helvie KE, Merrill MS, Santiago RA, O’Connor EP, Jeong SH, Leeson R, Barry R, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Oliver N, Marini L, Harshman LC, Tolaney S, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love CJ, Meyerson M. “Reproducible and scalable approach for whole-exome sequencing of cell-free DNA from patients with metastatic cancer.” Nature Communications (2017). 8:1324. PMID: 29109393
Bierie B, Pierce S., Kroger C, Stover DG, Pattabiraman D, Thiru P, Donaher JL, Reinhardt F, Chaffer C, Keckesova Z, Weinberg RA. “Integrin-beta 4 identifies tumor-initiating cell-enriched populations in triple-negative breast cancer.” Proceedings of the National Academy of Sciences U.S.A. (2017). 114:E2337-E2346. PMID: 28270621.
Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulsoon R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scalitri M, Juric D, Baselga J, Richardson AL, Rodic SJ, D’Andrea AD, Balmana J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. “CDK12 Inhibition Reverses de novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.” Cell Reports (2016). 2016 17:2367-2381. PMID: 27880910.
Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. “Patient-derived xenografts of HER2-positive breast cancer brain metastases facilitate discovery of a therapeutic strategy yielding durable remissions.” Nature Medicine. (2016). 22:723-6. PMID: 27270588.
Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. “The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.” Clinical Cancer Research (2016). 22:6039-6050. PMID: 27330058.
Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. “CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer.” Cell (2015) 163:174-86. PMID: 26406377.
Shu S, Lin CY, He HH, Witwicki RM, Roberts JM, Tabassum DP, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D’Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carrroll JS, Long H, Brown M, Liu XS, Meyere CA, Bradner JE, Polyak K. “Response and Resistance to BET bromodomain inhibitors in triple negative breast cancer.” Nature. (2016). 529:413-417. PMID: 26735014.
Stover DG & Zerillo J. “Morbidity and Mortality Revisited: Applying a New Quality Improvement Paradigm in Oncology.” Journal of Oncology Practice. (2015). 1:e428-33. PMID: 25901054.
Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JB, Vnencak-Jones C. “Allele-Specific PCR for KRAS and BRAF in a Cohort of Patients with Colorectal Cancer Submitted for Microsatellite Testing.” Clinical Colorectal Cancer (2013) 12:168. PMID: 23773459.
Semler MW,* Stover DG,* Copland A, Hong G, Johnson MJ, Kriss MS, Otepka H, Wang L, Christman BW, Rice TW. “Flash mob research: A single day, multi-center, resident-directed study of respiratory rate.” CHEST (2013) 143:1740. PMID: 23197319. *Indicates authors contributed equally.
Theobald CN,* Stover DG,* Choma NN, Hathaway J, Green JK, Peterson NB, Sponsler KC, Vasilevskis EE, Kripalani S, Sergent J, Brown NJ, Denny JC. “Effect of the ACGME 16-hour rule on internal medicine educational opportunities.” Academic Medicine. (2013) 88:512. PMID: 23425987. *Indicates authors contributed equally.
Stover DG, Reddy VK, Shyr Y, Savani B, Reddy N. “Impact of prior rituximab therapy on lymphocyte recovery and autologous stem cell transplant outcome for diffuse large B cell lymphoma.” Bone Marrow Transplant. (2012) 47:82-87. PMID: 21358691.
Bierie B, Chung CH, Parker J, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. “Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer.” Journal of Clinical Investigation. (2009) 119:1571-82. PMID: 19451693.
Bierie B, Gorska AE, Stover DG, Moses HL “TGF-β suppresses re-initiation of terminal differentiation during the second stage of mammary involution.” Journal of Cellular Physiology. (2009) 219:57-68. PMID: 19086032.
Adelani M, Stover DG, Halpern JL, Holt GE, and Schwartz HA. “Caveat arthroplasty.” Journal of Arthroplasty. (2009) 24:728-34. PMID: 18639434.
Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. “Phase I trial of pemetrexed and oxaliplatin administered every other week in patients with metastatic cancer.” Investigational New Drugs. (2008). 26:339-45. PMID: 18463792.
Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. “Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.” Cancer Research. (2008). 68:1809-1819. PMID: 18339861.
Lang JC, Borchers J, Danahey D, Smith S, Stover DG, Agrawal A, Malone JP, Schuller DE, Weghorst CM, Holinga AJ, Lingam K, Patel CR, Esham B. “Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF.” International Journal of Oncology (2002). 21:401-408. PMID: 12118338.